Description
Orforglipron Capsules | Non-Peptide Oral GLP-1 Agonist — Metabolic Research
Orforglipron (LY3502970) is an orally active, non-peptide small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike peptide-based GLP-1 agonists (semaglutide, liraglutide), orforglipron does not require syringe administration and is stable at room temperature. Phase III ATTAIN-DM trial data demonstrated up to 16.2% weight loss at 36 weeks. These capsules enable research into non-peptide GLP-1R activation mechanisms and oral versus injectable pharmacodynamic comparisons.
Mechanism of Action
- GLP-1R agonism (non-peptide) — binds the GLP-1 receptor orthosteric site as a small molecule, mimicking the actions of native GLP-1 without peptide structure
- Insulin secretion enhancement — glucose-dependent stimulation of pancreatic beta cells, reducing hypoglycaemia risk
- Appetite suppression — activates hypothalamic GLP-1R expressing neurons to reduce food intake
- Gastric emptying delay — slows gastric transit to reduce post-prandial glucose excursions
Research Areas
Orforglipron is studied in obesity, type 2 diabetes, NAFLD, and the comparative pharmacology of peptide vs. non-peptide GLP-1R agonists. Compare with Retatrutide vials (triple agonist) and Tirzepatide capsules (dual agonist) for comprehensive GLP-1R pathway research.
For Research Use Only. Rainbow Peptide supplies this compound exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. R. Henry –
Orforglipron capsules for our oral small-molecule GLP-1 receptor agonist research. Purity >99% by HPLC. GLP-1R activation in our cell model showed expected non-peptide agonist profile. COA detailed and traceable.
S. Bergman –
Good quality Orforglipron. Hard to source at high purity as a small molecule GLP-1R agonist. Rainbow Peptide delivered >99% confirmed. COA comprehensive. Fast delivery.
K. Osei-Bonsu –
Orforglipron capsules for our oral obesity mechanism research. Content purity >98.5%. COA thorough. GLP-1 receptor assay showed expected small-molecule agonist activity. Will continue ordering.